Significant Cross of Two Hundred Day Moving Average - ZBH
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 15 2025
0mins
Should l Buy ZBH?
Source: NASDAQ.COM
52 Week Range: ZBH's stock has a 52-week low of $89.24 and a high of $114.72, with the last trade recorded at $100.96.
Source of Information: The data regarding ZBH's stock performance was sourced from Technical Analysis Channel.com.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZBH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZBH
Wall Street analysts forecast ZBH stock price to fall
18 Analyst Rating
4 Buy
11 Hold
3 Sell
Hold
Current: 100.990
Low
88.00
Averages
100.47
High
120.00
Current: 100.990
Low
88.00
Averages
100.47
High
120.00
About ZBH
Zimmer Biomet Holdings, Inc. is a global medical technology company. It designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; CMFT; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its segments include Americas, EMEA, and Asia Pacific. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System and G7 Acetabular System. It also focused on a suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively. Its portfolio features imageless robotics through its ROSA Robotics platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Schwarzenegger to Speak at AAOS Annual Meeting
- Innovation Showcase: Zimmer Biomet will unveil its latest clinical and operational data at the 2026 AAOS Annual Meeting, emphasizing its leadership in orthopedic implants and robotic technologies, which is expected to attract significant attention from industry professionals.
- Keynote Speaker: Chief Movement Officer Arnold Schwarzenegger will serve as the Presidential Guest Speaker, engaging in discussions with the company's CEO and AAOS President about sustaining peak performance under pressure, thereby enhancing the brand's image.
- Technology Highlights: The exhibit will feature innovations such as the ROSA®Knee and TMINI® systems, aimed at improving surgical precision and patient outcomes through personalized surgical planning and accurate implant placement, further solidifying market competitiveness.
- Data Presentation: New safety and efficacy data for the Oxford® Cementless Partial Knee will be presented, along with efficiency metrics from new processes in ambulatory surgery centers, which are expected to positively influence industry standards.
See More
Zimmer Biomet Announces Q1 2026 Cash Dividend
- Quarterly Cash Dividend: Zimmer Biomet's Board of Directors has approved a cash dividend of $0.24 per share for Q1 2026, payable on or about April 30, 2026, aimed at rewarding shareholders and enhancing investor confidence.
- Record Date for Shareholders: The record date for this dividend is set for March 31, 2026, ensuring that shareholders who own stock by this date will receive the dividend, thereby encouraging long-term holding among investors.
- Company Background: Zimmer Biomet is a global leader in medical technology with over 90 years of industry experience, committed to enhancing patient experiences through innovative products and digital technologies, showcasing strong market competitiveness.
- Global Business Presence: The company operates in over 25 countries and sells products in more than 100 countries, reflecting the success of its globalization strategy aimed at meeting global health demands through continuous innovation.
See More
Zimmer Biomet Declares Quarterly Dividend of $0.24
- Quarterly Dividend Announcement: Zimmer Biomet has declared a quarterly dividend of $0.24 per share, consistent with previous payouts, indicating the company's ongoing ability to maintain stable cash flow, which is likely to bolster investor confidence.
- Dividend Payment Timeline: The dividend is payable on April 30, with a record date of March 31 and an ex-dividend date also on March 31, providing shareholders with a clear timeline that may attract more investors.
- Consecutive Dividend Record: The company has now announced a $0.24 dividend for seventeen consecutive quarters, reflecting its commitment to shareholder returns, which could enhance its attractiveness in the medical device sector.
- Future Outlook: Zimmer Biomet projects revenue growth of 1% to 3% for 2026 amid a U.S. sales force overhaul and innovation cycle, demonstrating management's confidence in future growth, which may influence shareholders' long-term investment perspectives.
See More
ZBH Stock Plummets 15% Amid Revenue Guidance Scrutiny
- Stock Price Drop: Zimmer Biomet Holdings, Inc. (ZBH) experienced a 15% stock decline on November 5, 2025, due to significant revenue misses in Latin America, resulting in a substantial loss of market value and investor confidence.
- Management Confidence Questioned: Despite senior management's claims of “very high” confidence in second-half growth in August 2025, subsequent order cancellations and revenue declines have raised concerns about whether management misled investors, potentially violating federal securities laws.
- Investigation Launched: Hagens Berman law firm is investigating whether ZBH issued overly optimistic financial guidance while concealing operational disruptions, urging affected investors to submit claims for their losses.
- Potential Legal Consequences: Should the investigation reveal misleading statements by ZBH, the company may face legal liabilities, further impacting its market reputation and shareholder trust.
See More
Analyzing Earnings in the Healthcare Sector: AZN, EW, and ZBH Compared
Earnings Reports in Healthcare Sector: Companies in the healthcare sector are reporting earnings that provide insights into their development progress and potential growth opportunities, particularly with the release of new drugs and medical devices.
AstraZeneca's Strong Performance: AstraZeneca reported a strong quarterly performance, with significant sales growth driven by its cancer medicines, which accounted for a large portion of its revenue, prompting positive investor sentiment.
Zimmer Biomet's Market Position: Zimmer Biomet is experiencing high demand for its orthopedic products, contributing to revenue growth, although it faces challenges from tariffs that may impact future earnings.
Investment Recommendations: Analysts are recommending specific stocks in the healthcare sector for investors to consider, highlighting potential growth opportunities and the importance of monitoring earnings and market conditions.
See More
Zimmer Biomet Q4 2025 Earnings Call Insights
- Sales Growth Performance: Zimmer Biomet reported net sales of $2.244 billion for Q4 2025, reflecting a 10.9% year-over-year increase, with U.S. business growing 5.7%, demonstrating the company's resilience in maintaining stable growth despite tariff pressures and the integration of three acquisitions.
- Profitability Improvement: The adjusted earnings per share reached $2.42, up 4.8% year-over-year, and despite dilution from the Paragon 28 transaction, the company successfully increased its adjusted gross margin to 72.4% through lower manufacturing costs and an optimized product mix.
- Cautious Future Outlook: Management anticipates organic revenue growth for 2026 to decline to 1% to 3%, with adjusted EPS guidance set at $8.30 to $8.45, reflecting a cautious stance regarding potential short-term disruptions from the U.S. sales force transition.
- Accelerated Strategic Transformation: The company is accelerating its transition to a specialized U.S. sales channel, expecting most of this transformation to be completed by the end of 2027, aiming to drive more durable and consistent growth, although short-term market volatility may be encountered.
See More
Schwarzenegger to Speak at AAOS Annual Meeting
- Innovation Showcase: Zimmer Biomet will unveil its latest clinical and operational data at the 2026 AAOS Annual Meeting, emphasizing its leadership in orthopedic implants and robotic technologies, which is expected to attract significant attention from industry professionals.
- Keynote Speaker: Chief Movement Officer Arnold Schwarzenegger will serve as the Presidential Guest Speaker, engaging in discussions with the company's CEO and AAOS President about sustaining peak performance under pressure, thereby enhancing the brand's image.
- Technology Highlights: The exhibit will feature innovations such as the ROSA®Knee and TMINI® systems, aimed at improving surgical precision and patient outcomes through personalized surgical planning and accurate implant placement, further solidifying market competitiveness.
- Data Presentation: New safety and efficacy data for the Oxford® Cementless Partial Knee will be presented, along with efficiency metrics from new processes in ambulatory surgery centers, which are expected to positively influence industry standards.
See More
Zimmer Biomet Announces Q1 2026 Cash Dividend
- Quarterly Cash Dividend: Zimmer Biomet's Board of Directors has approved a cash dividend of $0.24 per share for Q1 2026, payable on or about April 30, 2026, aimed at rewarding shareholders and enhancing investor confidence.
- Record Date for Shareholders: The record date for this dividend is set for March 31, 2026, ensuring that shareholders who own stock by this date will receive the dividend, thereby encouraging long-term holding among investors.
- Company Background: Zimmer Biomet is a global leader in medical technology with over 90 years of industry experience, committed to enhancing patient experiences through innovative products and digital technologies, showcasing strong market competitiveness.
- Global Business Presence: The company operates in over 25 countries and sells products in more than 100 countries, reflecting the success of its globalization strategy aimed at meeting global health demands through continuous innovation.
See More
Zimmer Biomet Declares Quarterly Dividend of $0.24
- Quarterly Dividend Announcement: Zimmer Biomet has declared a quarterly dividend of $0.24 per share, consistent with previous payouts, indicating the company's ongoing ability to maintain stable cash flow, which is likely to bolster investor confidence.
- Dividend Payment Timeline: The dividend is payable on April 30, with a record date of March 31 and an ex-dividend date also on March 31, providing shareholders with a clear timeline that may attract more investors.
- Consecutive Dividend Record: The company has now announced a $0.24 dividend for seventeen consecutive quarters, reflecting its commitment to shareholder returns, which could enhance its attractiveness in the medical device sector.
- Future Outlook: Zimmer Biomet projects revenue growth of 1% to 3% for 2026 amid a U.S. sales force overhaul and innovation cycle, demonstrating management's confidence in future growth, which may influence shareholders' long-term investment perspectives.
See More
ZBH Stock Plummets 15% Amid Revenue Guidance Scrutiny
- Stock Price Drop: Zimmer Biomet Holdings, Inc. (ZBH) experienced a 15% stock decline on November 5, 2025, due to significant revenue misses in Latin America, resulting in a substantial loss of market value and investor confidence.
- Management Confidence Questioned: Despite senior management's claims of “very high” confidence in second-half growth in August 2025, subsequent order cancellations and revenue declines have raised concerns about whether management misled investors, potentially violating federal securities laws.
- Investigation Launched: Hagens Berman law firm is investigating whether ZBH issued overly optimistic financial guidance while concealing operational disruptions, urging affected investors to submit claims for their losses.
- Potential Legal Consequences: Should the investigation reveal misleading statements by ZBH, the company may face legal liabilities, further impacting its market reputation and shareholder trust.
See More
Analyzing Earnings in the Healthcare Sector: AZN, EW, and ZBH Compared
Earnings Reports in Healthcare Sector: Companies in the healthcare sector are reporting earnings that provide insights into their development progress and potential growth opportunities, particularly with the release of new drugs and medical devices.
AstraZeneca's Strong Performance: AstraZeneca reported a strong quarterly performance, with significant sales growth driven by its cancer medicines, which accounted for a large portion of its revenue, prompting positive investor sentiment.
Zimmer Biomet's Market Position: Zimmer Biomet is experiencing high demand for its orthopedic products, contributing to revenue growth, although it faces challenges from tariffs that may impact future earnings.
Investment Recommendations: Analysts are recommending specific stocks in the healthcare sector for investors to consider, highlighting potential growth opportunities and the importance of monitoring earnings and market conditions.
See More
Zimmer Biomet Q4 2025 Earnings Call Insights
- Sales Growth Performance: Zimmer Biomet reported net sales of $2.244 billion for Q4 2025, reflecting a 10.9% year-over-year increase, with U.S. business growing 5.7%, demonstrating the company's resilience in maintaining stable growth despite tariff pressures and the integration of three acquisitions.
- Profitability Improvement: The adjusted earnings per share reached $2.42, up 4.8% year-over-year, and despite dilution from the Paragon 28 transaction, the company successfully increased its adjusted gross margin to 72.4% through lower manufacturing costs and an optimized product mix.
- Cautious Future Outlook: Management anticipates organic revenue growth for 2026 to decline to 1% to 3%, with adjusted EPS guidance set at $8.30 to $8.45, reflecting a cautious stance regarding potential short-term disruptions from the U.S. sales force transition.
- Accelerated Strategic Transformation: The company is accelerating its transition to a specialized U.S. sales channel, expecting most of this transformation to be completed by the end of 2027, aiming to drive more durable and consistent growth, although short-term market volatility may be encountered.
See More
